Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.02 – $0.29
24% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — |
| R&D | $0 | $238.8K | $726.1K | $962.7K | $133.7K | $1.5K |
| Operating income | −$183.3K | −$1.0M | −$6.0M | −$3.8M | −$2.4M | −$3.1M |
| EBITDA | −$183.3K | −$1.0M | −$6.0M | $3.6M | −$4.6M | −$2.4M |
| Net income | −$230.1K | −$1.2M | −$6.5M | −$11.7M | −$7.7M | −$4.0M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.11 | -0.39 | -0.78 | -1.20 | -0.57 | -0.20 |
Annual figures · source: Financial Modeling Prep
BIOVAXYS TECHNOLOGY CORP
No one on the platform currently holds BVAXF.
No tracked institution reports a position in BVAXF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-09-11 | 1-for-10reverse |
| 2020-04-28 | 2-for-1 |
No one on the platform has traded BVAXF yet.
| $8M |
| — |
| FAMDFFutura Medical plc | $0.00 | -70.00% | $712597 | — |
| KNBIFKane Biotech Inc. | $0.02 | +0.00% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$BVAXF Government validation via programs like CBRN would be huge for DPX platform credibility. In the meantime, the positive 2026 clinical readouts in ovarian/bladder cancer keep the science moving forward. Hang in there! platforms like this take time but have big upside.
View on StockTwits ↗Precision medicine, obesity, gene editing and immunotherapy continue to dominate healthcare headlines. $BVAXF $VKTX $CRSP $BEAM $SMMT.
View on StockTwits ↗$BVAXF $BIOV.CSE On X/Twitter regarding the US Govt Tweet: Question: May we ask if this was a BioVaxys specific request from the capability program or a BAA request BioVaxys is responding to? BIOVAXYS Response: CPE CBRND is a separate but parallel organization to DTRA and BARDA that is under the 'umbrella' of the US Army, and they have their own discretionary budget. This meeting is not in response to any BAA; its based on a request from CPE CBRND. Hope this helps!
View on StockTwits ↗$BVAXF similar to my post on ceo, I'm getting used to the annual cto holiday. This years may just be a bonus length of time. Trade halts do have the benefit of denying the fake market the opportunity for manipulation thus keeping the price stable. 😜 Of course, that's a joke in itself just like passin is as ceo. Who'd even take a 2nd look here? Remember passin when the next annual vote comes around....
View on StockTwits ↗$BVAXF Put an order down at .06. Fidelity shows someone bought there yesterday. I know every broker is different. 🤪
View on StockTwits ↗$BVAXF $BIOV.CSE https://x.com/biovaxys/status/2069819444390510812?s=20
View on StockTwits ↗$BVAXF $BIOV.CSE Interesting note...The DPX Anthrax study appeared in Nature Vaccines in 2019. https://www.nature.com/articles/s41541-019-0102-z
View on StockTwits ↗$BVAXF Fidelity appears to be incorrect. This is an active eTrade account.
View on StockTwits ↗$BVAXF Very difficult to watch all this opportunity and knowing they are WAY behind on filling AND put us in Canada in a trade halt for failure to file. This is getting close to a violation of fiduciary duty and continuous disclosure, which would be yet another liability for stockholders.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.